FAQs

Retatrutide is a research peptide currently being studied for its potential role in weight management and metabolic health. It is often compared with GLP-1 receptor agonists (a class of medicines used in type 2 diabetes and obesity research). Retatrutide is not an approved prescription medication and is supplied strictly for laboratory and research purposes only.

Retatrutide is commonly available in research pens that contain a lyophilised (freeze-dried) peptide in liquid solution. These pens are designed for precise dosing in laboratory settings. While many people discuss it in relation to “injections,” our products are provided for research use only, not for human self-administration.

No. Retatrutide is not licensed as a prescription medicine in the UK or internationally. It is still undergoing clinical studies and has not been approved for medical use. Any products offered on this website are strictly research supplies and should never be used as treatment. Always seek medical advice from a qualified professional before making decisions about your health.

Because Retatrutide is still in the research stage, its full safety profile is not yet known. However, since it works on similar pathways to other GLP-1 receptor agonists, possible side effects under investigation include gastrointestinal issues such as nausea, vomiting, diarrhoea, or constipation. These findings are based on early studies only and may not reflect all risks.